双阳喉痹通颗粒抗急性红白血病机制研究
本研究探讨双阳喉痹通颗粒(SY)治疗急性红白血病(AEL)的分子机制与活性成分。采用F-MuLV诱导的小鼠红白血病模型,结合网络药理学与RNA测序,发现SY通过PI3K/AKT和JAK/STAT通路抑制HEL细胞增殖并诱导凋亡,延长小鼠生存期且无肝肾毒性;血清中鉴定144种化合物, xanthohumol(XAN)抑制增殖作用最显著。
要点
- SY可修复F-MuLV诱导的小鼠脾损伤并促进红系分化。
- SY通过调控PI3K/AKT和JAK/STAT通路诱导HEL细胞凋亡。
- SY血清移行成分中xanthohumol抑制HEL细胞增殖作用最强。
核心结论
- SY延长红白血病小鼠生存期且不诱导肝肾毒性。
- SY通过PI3K/AKT和JAK/STAT通路抑制HEL细胞增殖并诱导凋亡。
- SY血清移行成分中鉴定144种化合物,xanthohumol显著抑制HEL细胞增殖。
研究设计与样本
- 采用Friend鼠白血病病毒(F-MuLV)建立小鼠红白血病模型。
- 体外使用人红白血病HEL细胞系进行机制研究。
- 结合网络药理学与RNA测序筛选差异基因和调控通路。
主要发现
- SY显著修复F-MuLV诱导的小鼠脾损伤并降低脾脏CD71/Ter119比值。
- SY提高脾脏免疫细胞(CD3、CD4、CD8a、B220、CD11b)比例并延长小鼠生存期。
- SY以时间和剂量依赖方式诱导HEL细胞凋亡并抑制增殖。
- SY上调Bad、cleaved caspase-3/9、cleaved PARP及p-JAK2、p-STAT3,下调Bcl-xl、p-PI3K、p-AKT。
- UHPLC-Q-TOF/MS鉴定SY血清移行成分共144种化合物,xanthohumol抑制HEL细胞增殖作用最显著。
关键数值与推荐
- SY降低红白血病小鼠脾脏CD71/Ter119比值。
- SY提高脾脏CD3、CD4、CD8a、B220、CD11b免疫细胞比例。
- SY血清移行成分中鉴定144种化合物,其中8种评估抗红白血病活性。
临床怎么用
- SY可作为红白血病辅助治疗的潜在中药复方,但需进一步临床验证。
- xanthohumol可作为SY抗红白血病活性的质控或活性标志物候选。
局限性
- 机制研究主要基于细胞系和动物模型,缺乏临床数据。
- SY多成分协同作用及具体靶点网络仍需深入解析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Traditional Chinese Medicine (TCM) posits that the onset of leukemia is often attributed to internal deficiencies and imbalances between yin and yang. Shuangyang Houbitong granules (SY) have been used in folk medicine to treat leukemia by balancing the yin-yang. However, the molecular mechanisms in which SY exerts anti-leukemia effects remain largely unexplored. AIM OF THE STUDY: To investigate the molecular mechanisms and bioactive ingredients of SY for the treatment of acute erythroleukemia (AEL). MATERIALS AND METHODS: A mouse model of erythroleukemia was established using Friend murine leukemia virus (F-MuLV). The therapeutic effect of SY in erythroleukemic mice was assessed through various methods, including examining spleen morphology, measuring biochemical parameters, evaluating erythrocyte differentiation, analyzing splenic immune cell markers, conducting histopathological staining, and recording survival rates. Erythroleukemia cell viability and apoptosis were measured using MTT assays, flow cytometry, and JC-1 staining. Furthermore, network pharmacology and RNA sequencing (RNA-seq) were employed to identify differentially expressed genes and explore regulatory pathways. Western blotting was utilized to detect relevant protein expression, and the components of SY were analyzed using UHPLC-Q-TOF/MS. RESULTS: The vivo experiments revealed that SY significantly repaired F-MuLV-induced splenic injuries in erythroleukemic mice. Flow cytometry analysis indicated that SY promoted differentiation towards mature erythrocytes, markedly reducing the ratio of CD71/Ter119 in the spleens of the treated mice. In addition, SY enhanced the proportion of immune cells (CD3, CD4, CD8a, B220, and CD11b), effectively activating the immune system and prolonging the survival of the mice. In vitro, SY significantly induced apoptosis in human erythroleukemia (HEL) cells in a time- and dose-dependent manner, inhibiting HEL cell proliferation. The results of network pharmacology and RNA sequencing suggested that SY may inhibit HEL cell proliferation by affecting the PI3K/AKT, JAK/STAT signaling pathways. Consistent with the above findings, SY increased the expression of apoptosis-related proteins (Bad, cleaved caspase-3/9, and cleaved PARP) and key proteins of the JAK/STAT signaling pathway (p-JAK2, p-STAT3), while down-regulating Bcl-xl and proteins related to the PI3K/AKT signaling pathway (p-PI3K and p-AKT) in the HEL cells. Using UHPLC-Q-TOF/MS analysis, a total of 144 compounds were identified in the component of SY that entered the serum. We evaluated the anti-erythroleukemia activity of eight selected compounds (luteolin, genistin, isofraxidin, glabridin, isovitexin, bergenin, diosmetin, and xanthohumol) from the initial 144 compounds. Notably, xanthohumol (XAN) exhibited the most significant inhibition of HEL cell proliferation, inducing apoptosis and activating apoptosis-related proteins in HEL cells. CONCLUSION: SY increased the survival rate and prolonged life span in erythroleukemia mice without inducing hepatorenal toxicity. SY inhibits HEL cell proliferation and induces apoptosis through PI3K/AKT and JAK/STAT signaling pathways. A total of 144 compounds were identified in the component of SY that entered the serum, XAN showed a significant inhibition of HEL cell proliferation.
引用
- Liu X, Wang B, Mou Y, et al. Mechanism of Shuangyang Houbitong granules against acute erythroleukemia through PI3K/AKT and JAK/STAT signaling pathways. J Ethnopharmacol. 2025. PMID: 40381820. doi:10.1016/j.jep.2025.119979
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。